Let's talk medical research

Clinical trials help people access tomorrow’s treatments today. In the age of precision medicine and tumor profiling, this statement is particularly true for oncology patients. According to a recent ProPublica article, even in Phase I trials, 20% of clinical trial participants now see a reduction in tumor size, compared with 5% of participants in the 1990s.

Every conversation about minority participation in medical research inevitably winds up with the “T” word – Tuskegee.

At Antidote, we aim to make it easy for researchers and patients to connect. And a big part of that work is creating opportunities for people to learn more about medical research and dispelling myths about medical research participation, both for patients and researchers.